News Release: July 29, 2025
Atractylenolide Price, Production, Latest News and Developments in 2025
Atractylenolide price trend and production News
Atractylenolide Price Trend in Past Five Years and Factors Impacting Price Movements (2019–2024)
Over the past five years, the global Atractylenolide price trend has shown considerable fluctuations due to various dynamic factors including raw material availability, demand from traditional medicine sectors, international trade restrictions, and advancements in extraction technologies. From 2019 to 2024, prices have ranged from approximately $4,700/MT to $7,300/MT, with distinct phases of decline and resurgence driven by supply chain adjustments and macroeconomic developments.
In 2019, the average Atractylenolide price stood at around $4,800/MT. The market was relatively stable, supported by consistent demand in the pharmaceutical and herbal supplement sectors. However, 2020 saw a sharp rise in prices, peaking at $6,300/MT, as pandemic-driven lockdowns and transportation restrictions affected production and cross-border movement of raw herbs used for Atractylenolide extraction.
The 2021 Atractylenolide price news reflected a mild correction as supply chains adjusted and production resumed. The price averaged $5,800/MT, impacted moderately by increased global interest in natural immunity boosters, which kept demand steady.
By 2022, prices saw another spike to around $7,300/MT, mainly driven by inflationary pressures on herb collection, rising labor costs, and an upsurge in international orders from traditional medicine manufacturers. Climate variability also affected harvests in Asia, further tightening supply.
In 2023, the Atractylenolide price news pointed towards a slight decline, stabilizing around $6,600/MT, as newer synthetic routes and improved yields from wild sources came into play. However, rising logistics costs and trade tariffs continued to cause periodic volatility.
In early 2024, the price eased to $6,200/MT, amid subdued global demand and increasing inventories from oversupply in late 2023. Key producers, especially in East Asia, started adopting advanced extraction technologies, improving efficiency and reducing overall costs per ton.
Factors influencing the Atractylenolide price trend included:
- Volatile availability of Atractylodes macrocephala roots, the primary source material.
- Export duties and phytosanitary regulations imposed by key producing countries.
- Growing adoption of Atractylenolide in modern pharmacological applications, pushing up Atractylenolide sales volume in certain quarters.
- Research and development investments, especially in synthetic alternatives, impacting natural product prices.
- Currency fluctuations and economic stability of exporting nations, which directly affected pricing strategies.
Overall, the five-year trajectory suggests that while the Atractylenolide market is sensitive to natural production cycles, it remains highly influenced by technological shifts and global demand-supply alignments.
Atractylenolide Price Trend Quarterly Update in $/MT (2024–2025)
- Q1 2024: $6,200/MT
- Q2 2024: $6,000/MT
- Q3 2024: $6,300/MT
- Q4 2024: $6,150/MT
- Q1 2025: $6,450/MT
- Q2 2025: $6,700/MT (estimated)
- Q3 2025: $6,800/MT (projected, based on demand surge in pharma segment)
- Q4 2025: $6,650/MT (estimated stabilization due to new supply sources)
The quarterly Atractylenolide price news from early 2025 indicates a gradual increase, mainly driven by a spike in pharmaceutical industry demand across North America and the Asia-Pacific region. Market analysts predict continued upward movement into Q3 due to seasonal reduction in herb harvesting.
Global Atractylenolide Import-Export Business Overview
The global trade of Atractylenolide has undergone significant transformation over the last few years, reflecting changes in market access, extraction technology, and shifting consumer preferences. In 2025, the import-export dynamics show a competitive environment shaped by both traditional and modern usage applications.
Key Exporting Nations:
China continues to dominate Atractylenolide production and exports, contributing over 70% of the global supply. The provinces of Zhejiang, Anhui, and Yunnan remain central to production, given the abundance of Atractylodes roots. The Chinese government has provided incentives for semi-synthetic manufacturing processes, which has helped stabilize domestic Atractylenolide price trends and improve global competitiveness.
India, although a smaller player, has increased exports of herbal derivatives, including Atractylenolide, particularly to Southeast Asia and the Middle East. Recent investments in botanical extraction facilities have improved export volumes and allowed for better compliance with international phytochemical standards.
Key Importing Nations:
South Korea and Japan are among the largest importers due to their thriving traditional medicine markets. In recent years, regulatory alignment and free trade agreements have eased import restrictions, allowing higher Atractylenolide sales volume into these countries. Additionally, both nations have strict quality control systems, encouraging exporters to maintain high purity standards.
The European Union, particularly Germany and France, has also become a notable destination for Atractylenolide, especially for its applications in nutraceuticals and cosmetic formulations. However, stringent compliance protocols and certification requirements have posed challenges for new exporters.
In the United States, the rise of alternative medicine and wellness products has triggered increasing demand. The FDA’s conditional acceptance of certain herbal compounds for research purposes has paved the way for wider market access. This has also fueled interest in local production and joint ventures with Asian manufacturers.
Recent Trade Developments in 2025:
- A China-South Korea trade agreement signed in March 2025 introduced reduced tariffs on Atractylenolide and related herbal derivatives, leading to a measurable price drop in South Korean markets.
- India expanded its Atractylenolide production capacity in April 2025, with two new facilities commissioned in Uttarakhand and Himachal Pradesh. This is expected to increase annual production by 18% and bolster export readiness.
- In May 2025, the European Medicines Agency announced updated guidelines on acceptable Atractylenolide concentrations in over-the-counter herbal formulations, opening new market opportunities for certified producers.
- Ongoing talks between Vietnam and China regarding bilateral herbal medicine trade could open another export pathway by late Q4 2025, potentially impacting Atractylenolide price news in Southeast Asia.
Challenges in Global Trade:
Despite the promising developments, Atractylenolide trade still faces hurdles. Regulatory inconsistencies, particularly in labeling and quality standards, often delay exports. Intellectual property concerns around proprietary extraction methods also create hesitancy among joint venture partners.
Transportation logistics, especially for temperature-sensitive herbal compounds, can add significant costs. Additionally, some importing countries have limitations on herbal medicine imports, demanding complex approvals that extend lead times and increase final prices.
Future Outlook:
Looking forward, global trade in Atractylenolide is expected to grow at a moderate pace, driven by rising awareness, improved processing technologies, and diversified application areas. However, market participants must stay agile in adapting to changing trade policies and quality expectations.
As of mid-2025, the international Atractylenolide price trend remains on a cautious upward trajectory, with estimates suggesting an average global export price of $6,800/MT by year-end. The demand-supply balance appears stable, but rising operational costs and evolving regulations may influence future pricing strategies.
For stakeholders involved in the Atractylenolide trade, 2025 is proving to be a year of both consolidation and expansion. Companies that can invest in sustainability, technological upgradation, and regulatory compliance are well-positioned to benefit from emerging opportunities in this niche yet growing market.
To explore the complete report and request a free sample, visit https://datavagyanik.com/reports/atractylenolide-market/
Atractylenolide Production Trends by Geography
Atractylenolide production is primarily influenced by regional access to Atractylodes macrocephala, the traditional herb used as the main raw material. The global production landscape is geographically concentrated in Asia, with a growing interest from other regions, especially due to increasing demand in pharmaceuticals and traditional medicine industries. In 2025, several countries are making significant strides in expanding or modernizing their production capacities.
1. China
China remains the dominant global producer of Atractylenolide, accounting for the largest share of the market. The availability of Atractylodes roots in provinces like Zhejiang, Sichuan, and Yunnan provides a natural advantage. In 2025, Chinese producers are transitioning from conventional extraction methods to semi-synthetic production techniques, allowing greater yields and purity. Local government support in the form of subsidies and research funding has helped scale up production. Manufacturers are also investing in sustainable sourcing and green extraction technologies to meet international quality standards.
2. South Korea
South Korea is another key player in Atractylenolide production, focusing more on quality than quantity. Korean facilities employ advanced purification technologies and rigorous quality control systems. In 2025, the Korean market is witnessing capacity expansion to cater to growing domestic demand, particularly from traditional Korean medicine manufacturers. The country’s research-driven approach is also enhancing extraction efficiency and standardization in end products.
3. India
India is emerging as a promising production hub for Atractylenolide due to increasing cultivation of Atractylodes-related species in northern states. Indian companies have started investing in botanical extraction facilities with a focus on export compliance. New production plants commissioned in Uttarakhand and Himachal Pradesh are expected to significantly raise India’s share in global output. The government is also facilitating herbal medicine standardization, which will likely boost international trust and production scalability.
4. Japan
Although not a high-volume producer, Japan maintains small-scale but highly specialized Atractylenolide production. The country emphasizes pharmaceutical-grade quality and precision. Due to stringent health and safety regulations, Japanese manufacturers are highly selective in sourcing and maintain state-of-the-art processing units. In 2025, local production is being ramped up slightly to reduce reliance on Chinese imports, especially for high-value formulations.
5. Southeast Asia (Vietnam, Thailand)
Vietnam and Thailand are beginning to explore commercial Atractylenolide production. While still in early stages, both countries have favorable agro-climatic conditions for Atractylodes cultivation. Government initiatives aimed at enhancing herbal exports are encouraging local pharmaceutical firms to invest in extraction units. Vietnam, in particular, has shown an uptick in cultivation trials and pilot extraction projects.
6. Europe
In Europe, Atractylenolide is not produced at scale but is increasingly included in research and therapeutic product development. Some pilot extraction facilities exist in Germany and the Netherlands, mainly for pharmaceutical R&D. However, due to climate limitations and regulatory hurdles, full-scale production is unlikely. Europe mostly imports Atractylenolide from Asia, but research-backed micro-production is expected to grow.
7. United States
The U.S. does not have native Atractylenolide production at industrial scale but is showing interest in localized extraction from imported raw materials. In 2025, a few biotech startups are experimenting with synthetic and semi-synthetic production routes. These efforts are aligned with the increasing demand for natural supplements and herbal formulations. If successful, the U.S. could emerge as a competitive producer in the long term.
Outlook
The global production trends of Atractylenolide in 2025 reflect a clear regional concentration in Asia, with China leading in volume and India catching up through infrastructure and quality enhancements. Technological adoption, sustainable practices, and regulatory alignment will play a critical role in shaping future growth across geographies. As demand continues to grow, more countries may seek to develop localized capabilities through joint ventures, research programs, and policy support.
Atractylenolide Market Segmentation
Key Market Segments of Atractylenolide:
- By Purity Level
- Low Purity (<95%)
- High Purity (≥95%)
- By Application
- Pharmaceuticals
- Nutraceuticals
- Traditional Medicine
- Cosmetic Products
- Research and Development
- By Form
- Powder
- Liquid
- Encapsulated
- By End-Use Industry
- Healthcare
- Personal Care
- Food Supplements
- Academic and Clinical Research
- By Distribution Channel
- Direct/Bulk Supply
- E-commerce
- Retail Pharmacies
- Distributors and Resellers
Explanation of Leading Segments
1. High Purity Atractylenolide (≥95%)
The demand for high-purity Atractylenolide is witnessing strong growth in 2025, driven by its widespread application in pharmaceuticals and clinical research. High-purity variants are preferred for injectable or oral drugs where consistency and minimal impurities are essential. Regulatory bodies in developed countries require ≥95% purity for use in registered therapeutic applications. As a result, producers across China, Korea, and Japan are increasingly focusing on this segment to enhance their global competitiveness.
2. Pharmaceuticals as Primary Application
The pharmaceutical segment holds the largest market share for Atractylenolide, particularly due to its anti-inflammatory, anticancer, and gastrointestinal applications. In 2025, several clinical trials are underway investigating Atractylenolide’s effectiveness in treating chronic diseases and metabolic syndromes. Pharmaceutical companies are also using Atractylenolide in combination therapies. The ongoing research is driving higher Atractylenolide sales volume, especially in North America, East Asia, and parts of Europe.
3. Traditional Medicine Market
This is one of the oldest and still fastest-growing application areas. Traditional Chinese Medicine (TCM), Korean herbal medicine, and Ayurveda frequently include Atractylenolide-based formulations. In 2025, renewed interest in alternative medicine, driven by health-conscious consumers and post-pandemic wellness trends, is resulting in higher demand from traditional medicine manufacturers. This segment benefits from deep-rooted cultural practices and expanding global acceptance.
4. Powder Form Leads in Market Share
Among the various forms, Atractylenolide in powder form is the most widely traded. It offers ease of blending in tablets, capsules, and teas. Powder is also more stable during transport and storage, making it a preferred form for bulk export. Liquid forms are popular in high-end cosmetic products and clinical settings, but limited by shorter shelf life and higher handling requirements.
5. Healthcare Industry Dominates End-Use
The healthcare sector continues to dominate the Atractylenolide market. Hospitals, therapeutic clinics, and pharmaceutical laboratories are major consumers. Demand is further boosted by rising awareness of plant-based compounds with minimal side effects. Regulatory authorities are supporting research, which is expanding the scope of end-use applications in chronic illness management.
6. E-commerce and Direct Supply Channels Expanding Rapidly
Distribution of Atractylenolide is shifting toward more agile channels. In 2025, direct-to-business (B2B) platforms and specialized herbal ingredient websites are gaining ground. E-commerce platforms are also playing a role in niche product distribution, especially for nutraceuticals and wellness products. Larger pharmaceutical companies still rely on bulk procurement from certified producers.
7. Regional Trends in Market Segmentation
In Asia-Pacific, the traditional medicine segment dominates, while in Europe and the U.S., pharmaceutical and research applications are growing swiftly. The cosmetic segment is showing promise in South Korea and Japan, where anti-aging and anti-inflammatory herbal products are trending. The food supplement segment, though still emerging, is likely to grow in regions with increasing acceptance of botanical ingredients in health foods.